Checkpoint Surgical, a privately held U.S.-based medical device company with proprietary neurostimulation technology for nerve protection and repair, raised $16 million of growth capital in August of 2021. One year later, with those investments in place, the company is shifting into growth mode, a move that comes with substantial changes. Executive Advisor Len Cosentino talks about the raise, his process for vetting investors and how Checkpoint is setting itself up for profitability.